Health Canada issued a conditional Notice of Compliance for Eisai and Biogen’s lecanemab (LEQEMBI) to treat adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease who are ApoE ε4 non‑carriers or heterozygotes and have confirmed amyloid pathology. The approval follows global regulatory activity and positions lecanemab as an amyloid‑targeting therapy authorized to slow cognitive and functional decline in early Alzheimer's. Eisai and Biogen said they will work with stakeholders to ensure access and diagnostic pathways for eligible patients across Canada.